BMS-908662 / Exelixis - LARVOL DELTA

Study of XL281 in adults with solid tumors (clinicaltrials.gov) - P1, N=180; Recruiting → Completed; Completion date: Dec ’10 → Oct ’11

Completion date • Trial completion • Melanoma • Oncology

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2; N=17; Completed; Sponsor: Bristol-Myers Squibb; N=120 ➔ 17

Clinical • Combination therapy • Enrollment change

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (clinicaltrials.gov) - P1; N=8; Completed; Sponsor: Bristol-Myers Squibb; Active, not recruiting ➔ Completed

Clinical • Combination therapy • IO Biomarker • Trial completion

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (clinicaltrials.gov) - P1; N=8; Completed; Sponsor: Bristol-Myers Squibb; N=120 ➔ 8

Clinical • Combination therapy • Enrollment change • IO Biomarker